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Abstract 
Hepatitis C virus (HCV) infection remains a major global health problem, with 
130-170 million chronically infected individuals at risk to develop severe liver 
disease, including hepatocellular carcinoma. Although the development of direct-
acting antivirals offers cure in large majority of patients, there are still a number 
of clinical challenges. These include DAA failure in a significant subset of 
patients, difficult-to-treat genotypes and limited access to therapy due to high 
costs. Moreover, recent data indicate that the risk for liver cancer persists in 
patients with advanced fibrosis. These challenges highlight the need for 
continued efforts towards novel therapeutic strategies for HCV. Over the past 
two decades, advances in HCV model systems have enabled a detailed 
understanding of HCV entry and its clinical impact. Many of the virus-host 
interactions involved in HCV entry have now been identified and explored as 
antiviral targets. Furthermore, viral entry is recognized as an important factor 
for graft reinfection and establishment of persistent infection. HCV entry 
inhibitors, therefore, offer promising opportunities to address the limitations of 
DAAs. Here, we summarize recent advances in the field of HCV entry and 
discuss perspectives towards the prevention and cure of HCV infection and 
virus-induced liver disease. 
 
 
 
 
 
 
Global impact of HCV infection. There are an estimated 130-170 million people 
worldwide who are chronically infected with hepatitis C virus (HCV) [1]. These 
individuals are at higher risk to develop severe liver disease, including cirrhosis and 
hepatocellular carcinoma (HCC) [1]. Although recent approval of direct-acting 
antivirals (DAAs) has improved the outlook for HCV patients, the risk for liver 
disease persists even after viral cure, once fibrosis has been established [2]. 
Furthermore, not all patients respond to therapy and the high costs of DAAs limit 
access to treatment even in high-resource countries [3-5]. A detailed, comprehensive 
knowledge of HCV entry will guide development of novel antiviral approaches [6, 7]. 
Here, we review recent insights into the HCV entry process and its clinical impact as 
an antiviral target. We also discuss perspectives to use our accumulating knowledge 
of HCV entry to develop strategies aimed at the prevention and cure of HCV infection 
and virus-induced liver disease. 
Molecular virology and cell biology of HCV entry. HCV is a member of the 
flaviviridae family, classified in the hepacivirus genus. HCV, with a positive sense 
single-stranded RNA genome of 9.6 kilo-base pairs, is a cytoplasmic-replicating virus 
[8]. The HCV capsid is surrounded by a host-derived lipid envelope, in which the E1 
and E2 glycoproteins are embedded, and is associated with serum lipoproteins such as 
apolipoprotein E (ApoE) [9]. 
The first step in HCV infection is low-affinity binding to heparan moieties in 
heparan sulfate proteoglycans on the surface of hepatocytes [10-12], an interaction at 
least partially mediated through virion-associated ApoE [13-15]. The cellular low-
density lipoprotein receptor (LDL-R) also interacts with virion-associated 
apolipoproteins to facilitate further binding [16-19]. Furthermore, the scavenger 
receptor class B type I (SR-B1) binds to virion-associated lipoproteins [20] and the 
HCV E2 protein [21]. The lipid transfer activities of SR-BI may expose regions of E2 
involved in interactions with other cellular factors, such as cluster of differentiation 
81 (CD81) [22, 23]. CD81, the first receptor identified for HCV, binds directly to E2 
[24] and also mediates critical post-binding events [25, 26], including activation of 
signaling pathways. Indeed, CD81 engagement was shown to activate signaling 
through the epidermal growth factor receptor (EGFR) [27] and Rho and Ras GTPases 
[28, 29]. 
Tight junction (TJ) proteins claudin-1 (CLDN1) and occludin (OCLN) have 
also been identified as HCV entry factors	 [30, 31]. CD81 interacts with CLDN1 to 
form a co-receptor complex [32], which along with the HCV particle is ultimately 
internalized into clathrin-containing endosomes [26]. Given that CD81-CLDN1 co-
receptor complex formation could be detected at basolateral membranes but not in TJ-
associated pools of CLDN1 [32], it is likely that the nonjunctional pool of CLDN1 
predominantly contributes to HCV entry. OCLN is another TJ protein required for a 
post-binding step of HCV entry [31, 33], although its specific role in entry has not yet 
been elucidated. 
Other cellular factors have been implicated in HCV entry, yet their functions 
remain enigmatic. For example, the Niemann-Pick C1-like 1 cholesterol absorption 
receptor interacts with virion-associated cholesterol to mediate binding or 
internalization steps [34]. Transferrin receptor 1 and cell death-inducing DFFA-like 
effector b are thought to be involved in late entry steps [35, 36]. Recently, the 
provirus integration site for Moloney murine leukemia virus (Pim1) kinase was 
identified as an additional HCV entry factor, perhaps by contributing to CD81-
CLDN1 receptor complex formation via PI3K-Akt signaling [37]. The serum 
response factor binding protein 1 (SRFBP1) also interacts with CD81 to coordinate 
host cell penetration [38]. SRFBP1 was proposed to mediate actin-dependent 
translocation following HBV receptor binding [38], and may also contribute to CD81-
CLDN1 co-receptor complex assembly. 
Ultimately, these virus-host interactions lead to the internalization of HCV 
into Rab5-containing early endosomes, where low pH induces viral fusion [26, 39]. 
The HCV fusion protein is still unknown. Although initial predictions pointed to E2 
as being the fusion protein, the recently solved crystal structure of the E2 core 
ectodomain suggests otherwise [40, 41]. Indeed, the E2 ectodomain is globular and 
did not undergo conformational changes when exposed to low pH [40, 41], suggesting 
that E2 acts through a novel mechanism or that E1 may be involved in inducing 
membrane fusion [42]. Further mechanistic studies, and likely a structure of the 
E1/E2 heterodimer, will be necessary to elucidate the fusion mechanism.  
Another route of HCV entry relies on direct cell-to-cell spread [43]. In this 
context, CD81, CLDN1 and SR-BI likely play key roles [43, 44], as do the viral 
envelope glycoproteins [45]. However, CD81 may be dispensable for cell-to-cell 
spread, at least in hepatoma cell lines [45]. Signaling pathways activated by EGFR 
may also contribute to cell-to-cell spread [27, 29]. Furthermore, virion-associated host 
factors such as ApoE have been implicated in cell-to-cell transmission [46]. 
HCV entry and liver disease. Viral entry is thought to play a major role in the 
pathogenesis of HCV infection. In the context of liver transplantation – which is 
severely hampered by rapid reinfection of the graft – it has been shown that viral 
quasispecies are rapidly selected following transplantation [47] and the resulting 
selection of viral variants contributes to pathogenesis. Indeed, escape from antibody-
mediated neutralization selects for viral variants with a highly efficient entry 
phenotype associated with altered receptor usage [48]. Mutations in E2 that modulate 
interactions with CD81 were implicated in mediating viral evasion at a post-binding 
step [49]. Altered usage of SR-B1 has also been observed [50], and increased levels 
of CLDN1 and OCLN modulate recurrence of HCV infection following liver 
transplantation [51]. These findings highlight viral entry as an important determinant 
for graft reinfection and the establishment of persistent infection. They also point to 
entry as an attractive therapeutic target, including preventing reinfection of the liver 
graft. 
Entry as a therapeutic target to address current limitations of DAAs. HCV entry 
offers many advantages as an alternative antiviral target. Entry inhibitors block the 
virus life cycle at a step before persistent infection can be established. Indeed, in the 
absence of de novo infection, hepatocyte turnover likely results in the elimination of 
infected hepatocytes and leads to clearance of infection [52]. Furthermore, host-
targeting agents aimed at entry factors have a higher genetic barrier for resistance, as 
the targets are not encoded by highly mutable viral genomes. Entry inhibitors also act 
synergistically with DAAs	 [53, 54], which would allow their incorporation into 
combination regimens. Interestingly, adding an entry inhibitor to DAA therapy 
reduces breakthrough of DAA-resistant variants, and entry inhibitors have been 
shown to have strong antiviral activity against DAA-resistant variants [55, 56]. 
Furthermore, many of the entry inhibitors including natural compounds may be 
produced at low costs offering a perspective to improve access to therapy in particular 
in countries or patients with limited resources.  The complex and multi-step HCV 
entry process offers many antiviral targets, and our accumulating knowledge of the 
virus-host interactions involved in HCV entry opens perspectives to develop antivirals 
targeting these steps. 
 
Entry inhibitors in preclinical and clinical development. Several compounds have 
been shown to block HCV binding. These include negatively charged small 
molecules, such as heparin, heparin-like compounds and polyphenols, which non-
specifically compete for binding to cell-surface HSPGs [10, 11, 57-63]. Other 
molecules target specific receptor binding. For example, the small molecule 281816 
(a dibenzothiepin derivative) disrupts the interaction between the HCV E2 protein and 
CD81 [64]. Similarly, oleanane-type triterpenes and the terpenoid saikosaponin b2 
bind to E2 and disrupt E2-CD81 interactions to inhibit HCV entry	 [65, 66]. 
Monoclonal antibodies against CD81 and SR-BI also interfere with HCV binding [67-
69] and to protect human liver chimeric mice from HCV infection [67-69]. Antibodies 
targeting SR-BI also reduced viral spread in already infected mice [68, 69]. 
Conversely, neutralizing antibodies targeting highly conserved epitopes on the viral 
envelope are also able to inhibit viral binding to CD81 [70-72]. Polyclonal 
immunoglobulins against HCV have been shown to protect human liver chimeric 
mice from HCV infection [73,74] and are being evaluated in a clinical trial in the 
context of graft reinfection (NCT01804829). Antibodies targeting non-virally 
encoded virion-associated epitopes such as ApoE also interfere with virion binding 
[9], as do peptides derived from ApoE [75]. 
Following the binding step, CD81-CLDN1 co-receptor complex formation is a 
critical step in HCV entry and therefore a most promising antiviral target. 
Furthermore, the CD81-CLDN1 co-receptor complex has no known physiological 
role, thereby limiting off-target effects. Monoclonal antibodies targeting the 
extracellular loops of CLDN1 inhibit CD81-CLDN1 association at a post-binding 
step. These antibodies inhibit infection by all major genotypes of HCV as well as 
patient isolates [76-78]. Furthermore, anti-CLDN1 monoclonal antibodies prevent 
HCV infection in human liver chimeric mice [52, 79]. Notably, one such antibody 
cured chronically infected mice in monotherapy [52], providing proof-of-concept for 
the use of entry inhibitors to cure chronic viral infection. Similarly, peptides targeting 
CLDN1 inhibit HCV entry at a post-binding step [80]. Small molecules targeting 
EGFR and EphA2, kinases involved in CD81-CLDN1 association, block HCV 
infection in cell culture and in human liver chimeric mice [27]. An EGFR inhibitor, 
erlotinib, is in clinical trials for chronic HCV infection (NCT02126137). 
Other post-binding steps in the HCV entry process are also targets. SR-BI 
receptor antagonists, including the arylketoamide ITX5061, inhibit HCV infection 
following binding [81]. ITX5061 is in a phase 1b clinical trial (NCT01560468). 
Arbidol (a synthetic indole) and silibinin (a flavonolignan from milk thistle) inhibit 
HCV clathrin-dependent endosomal trafficking by interfering with dynamin-2-
mediated membrane scission [82, 83]. Ezetimibe, a small molecule in clinical use as a 
cholesterol-lowering agent, inhibits HCV infection by interfering with NPC1L1 
internalization [34]. A clinical trial has been initiated to study its effects on 
chronically infected patients (NCT02126137). Recently, an antihistamine approved 
for allergy treatment, chlorcyclizine hydrochloride, was shown to inhibit infection by 
all genotypes of HCV, likely by targeting a late entry step linked to fusion	[84]. 
 Fusion is a critical step in the entry of enveloped viruses, including HCV. 
Indeed, the fusion inhibitor enfuvirtide – a peptide preventing conformational 
rearrangements of the human immunodeficiency virus (HIV) fusion protein – is 
approved to treat HIV infections. Our limited understanding of the HCV fusion 
mechanism currently prevents similar rational design approaches for HCV. However, 
peptides derived from E2 were shown to inhibit HCV infection at a post-binding step 
[85]. Furthermore, flunarizine (a piperazine derivative approved for the treatment of 
migraine headaches) inhibits HCV genotype 2 fusion by targeting E2 and a potential 
fusion peptide within E1 [42]. An antimalarial compound, ferroquine, inhibited HCV 
fusion, possibly through its interactions with E1 [86]. HCV infectivity inhibitor-1 
(HCV-II1) is thought to lock the HCV envelope in a pre-fusion conformation, thus 
blocking HCV fusion [87]. An HCV-specific triazine inhibitor, EI-1, interacts with E2 
to inhibit a post-binding pre-fusion entry step [88].  
Given that lipids play a central role in membrane fusion, molecules that target 
lipids also modulate fusion of enveloped viruses [89]. Lipid-mimicking rigid 
amphipathic fusion inhibitors insert into the lipid core of virion envelopes, where they 
block curvature changes required for fusion of HCV [90, 91]. Membrane fluidity is 
another critical determinant of fusion. Indeed, modulators of membrane fluidity such 
as phenothiazine derivatives, benzhydrylpiperazines and curcumin inhibit HCV fusion 
[92-94]. Similarly, polyunsaturated endoplasmic reticulum-targeting liposomes 
deplete cellular cholesterol levels to inhibit HCV fusion [95]. Clinical cholesterol-
lowering drugs such as statins and ezetimibe inhibit HCV infection [34, 96], perhaps 
at least partially by modulating membrane fluidity. Type II photosensitizers such as 
amphiphilic thiazolidine derivatives (e.g. LJ001) generate singlet oxygen species that 
oxidize phospholipids, leading to biophysical alterations in viral envelopes [97, 98]. 
These alterations were proposed to increase positive curvature and reduce membrane 
fluidity, both of which inhibit membrane fusion by increasing the energetics required. 
Clearly, many compounds acting by distinct mechanisms show great promise 
in pre-clinical models; ultimately, clinical studies will determine the future role of 
HCV entry inhibitors. Several clinical trials are ongoing and will reveal the 
perspectives for entry inhibitors against HCV to prevent liver graft reinfection or to 
treat patients who fail DAA-based therapy.  
Perspectives. Since the discovery of HCV approximately 25 years ago, major 
advances in HCV model systems have enabled a detailed understanding of HCV 
virology and virus-host interactions. These advances allowed the development of 
DAAs targeting virus replication steps, which have dramatically improved the 
standard of care for chronically infected patients. Recent advances in the 
understanding of HCV entry and its clinical impact have set the stage for further 
development of novel antiviral approaches, which could address the current 
limitations of DAAs including resistance/failure and access to therapy.  
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Table 1. HCV inhibitors targeting different steps of the HCV entry process. Inhibitors 
in bold are in clinical trials. 
Entry step Compound  Target/Mechanism References 
Primary binding Heparin-like molecules 
Epigallocatechin gallate 
Tannic acid 
Gallic acid 
Delphinidin 
HCV-HSPG interaction 
HCV-HSPG interaction 
Docking of HCV at cell surface 
Docking of HCV at cell surface 
Docking of HCV at cell surface 
[6, 7, 8, 53] 
[54-56] 
[57] 
[58] 
[59] 
Specific binding 281816 
Oleanane-type triterpenes 
Saikosaponin b2 
Anti-CD81 antibody 
Anti-SRBI antibody 
Anti-ApoE antibody 
Neutralizing antibodies 
Polyclonal anti-HCV IgG 
ApoE-derived peptide 
HCV E2-CD81 interaction 
HCV E2-CD81 interaction 
HCV E2-CD81 interaction 
HCV E2-CD81 interaction 
HCV-SRBI interaction 
HCV-associated ApoE-HSPG interaction 
HCV E1/E2 
HCV E1/E2 
HCV-associated ApoE-HSPG interaction 
[60] 
[61] 
[62] 
[63] 
[64, 65] 
[5] 
[66-68] 
[69, 70] 
[71] 
Post-binding Anti-CLDN1 antibodies 
CLDN1-derived peptide 
Erlotinib 
ITX5061 
CD81-CLDN1 coreceptor complex  
CD81-CLDN1 coreceptor complex  
CD81-CLDN1 coreceptor complex; signaling 
SRBI lipid transfer activity 
[48, 72-75] 
[76] 
[23] 
[77] 
Internalization Arbidol 
Silibinin 
HCV endosomal trafficking 
HCV endosomal trafficking 
[78] 
[79] 
Fusion Flunarizine 
Ferroquine 
RAFIs 
Phenothiazines 
Benzhydrylpiperazines 
Curcumin 
Polyunsaturated liposomes 
Statins  
Ezetimibe 
Photosensitizers (LJ001) 
HCV genotype 2 fusion (E1 and/or E2) 
HCV fusion (E1) 
HCV envelope curvature 
HCV envelope fluidity 
HCV envelope fluidity 
HCV envelope fluidity 
Cellular membrane (cholesterol depletion) 
Cellular membrane (cholesterol depletion) 
Cellular membrane (cholesterol depletion) 
Lipid oxidation (viral envelope) 
[38] 
[81] 
[85, 86] 
[87] 
[88] 
[89] 
[90] 
[91] 
[30] 
92, 93] 
 
 
 
 
 
 
 
	
Figure 1. A simplified scheme of the HCV entry pathway, showing major viral and 
cellular determinants of viral entry. Inhibitors targeting the main entry steps are also 
shown.  
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